-
05 Robert LaCaze-拜耳全球肿瘤研发及业务新方向
Robert LaCaze 总裁拜耳全球肿瘤事业部总裁Robert LaCaze is a senior bio-pharmaceutical executive with more than 28 years of experience in the industry. Throughout his career he has served in multiple operational and strategic roles involving the US, EU, China and Japan.Mr. LaCaze joined Bayer Pharmaceuticals in October 2015 and currently serves as the Executive Vice President and Head of the Oncology Strategic Business Unit (SBU). The Oncology SBU is responsible for all strategy in Bayer’s Oncology Business and consists of: Clinical Development, Regulatory Affairs, Strategic Medical Affairs, Strategic Marketing and Commercialization, Oncology Market Access and Clinical Operations. He is also a member of Bayer’s Pharmaceutical Executive Committee.Prior to joining Bayer, Mr. LaCaze spent over 25 years with Bristol Myers Squibb serving in multiple roles including his two most recent roles of Senior Vice President and Head of Product and Portfolio Strategy for Worldwide Commercialization and Senior Vice President, Global Oncology Commercialization in which he was responsible, with his R&D counterpart, for setting the vision and strategy for the Immuno-Oncology (I-O) franchise. He oversaw the early strategy for Nivolumab and lead the Global Launch of Ipilimumab BMS’s first I-O drug and the Global launch of BMS’s first target therapy, Dasatinib. Both of which have achieved more than $1B in annual sales.Mr LaCaze is a member of AACR and also serves as a member of the College of Business Advisory Board for Louisiana Tech University, his alma mater. He, his wife, and two sons reside in Robbinsville NJ.
2018-04-05 38188 看过 免费 -
03 韩国宏-介入新思路：建立 TACE 技术与靶向药物治疗最佳联合
韩国宏 教授空军军医大学（第四军医大学）西京医院消化介入科主任主任医师、教授、博导亚太原发性肝癌理事会理事（APPLE Council Member）中华医学会放射学分会介入学组副主任委员中国研究型医院学会介入专委会副主任委员中华医学会消化学分会介入协作组副组长卫计委原发性肝癌诊疗规范专家委员会委员（2011 版和 2017 版）2017 年以第一完成人获军队科技进步一等奖2016 年作为主要成员获国家科学进步奖创新团队奖2012 年至 2016 年连续五年荣登中国名医百强榜（介入放射治疗科）2010 年以来作为第一或通讯作者在 Gut、Nat Rev Gastro & Hepatol 、 Hepatology 、 J Hepatol 、 Ann Oncol 、 Clin Cancer Res 、 Radiology、 Thromb & Haemost 等权威杂志发表 SCI 同行评议论文 129 篇
2018-04-05 72504 看过 免费
热门资讯
- 【新膝望】第七届风湿新秀争霸全国总结会 展示活动开启
- 北京天坛医院冯涛教授团队建模研究在BMJ发表：预测到2050年全球帕金森病流行病学趋势
- 两会开麦啦！眼科大咖×AI先锋高端对话：如何用科技"看"未来？
- 舒巴坦-度洛巴坦：应对CRAB感染的新希望
- 从临床实践中来，到临床实践中去——高强度NPPV治疗AECOPD的中国方案荣登JAMA | 呼吸临床研究展播
- 2025医学盛会｜Seldinger技术×高质量透析：前沿实战演练与深度研讨
- 国考导向，质控为先｜灯塔计划——“三医”协同助力公立医院高质量发展交流会顺利召开
- 研究速递：舒巴坦-度洛巴坦与17种常见抗菌药物均无拮抗作用
- 【招商函】灯塔计划——血液科领导力提升项目 0419深圳
- 攻克头影测量难题，华西正畸团队带你突破瓶颈【7天训练营自由开营，不限时学习】
